非酒精性脂肪性肝病患者血清HIF-1α、HMGB1和脂联素水平变化及其与颈动脉粥样硬化的关系研究*

doi:10.3969/j.issn.1672-5069.2024.02.010

实用肝脏病杂志 ›› 2024, Vol. 27 ›› Issue (2): 198-201.doi: 10.3969/j.issn.1672-5069.2024.02.010

非酒精性脂肪性肝病患者血清HIF-1α、HMGB1和脂联素水平变化及其与颈动脉粥样硬化的关系研究^*

郑波, 哈丽达·夏尔甫哈孜, 谈理

610100 成都市四川护理职业学院附属医院/四川省第三人民医院消化内科(郑波,谈理);新疆医科大学第一附属医院消化病二科(哈丽达·夏尔甫哈孜)

收稿日期:2023-09-07 出版日期:2024-02-10 发布日期:2024-03-08
通讯作者: 哈丽达·夏尔甫哈孜,E-mail:18509914924@163.com
作者简介:郑波,男,35岁,大学本科,主治医师。E-mail:18030725221@163.com
基金资助:
^*四川省科技厅科研基金资助项目(编号:2021LJ0240001)

Changes of serum HIF-1α, HMGB1 and adiponectin levels in patients with non-alcoholic fatty liver diseases and their correlation to carotid atherosclerosis

Zheng Bo, Halida.Xiaerfuhazi, Tan Li

Department of Gastroenterology, Third Provincial People's Hospital, Affiliated to Sichuan Professional College of Nursing, Chengdu 610100, Sichuan Province, China

Received:2023-09-07 Online:2024-02-10 Published:2024-03-08

摘要/Abstract

摘要： 目的探讨非酒精性脂肪性肝病(NAFLD)患者血清低氧诱导因子-1α(HIF-1α)、高迁移率族蛋白1(HMGB1)和脂联素(APN)水平变化及其与颈动脉粥样硬化(CAS)的关系。方法 2018年5月～2023年3月我院诊治的NAFLD患者158例(其中合并CAS者71例), 使用Fibrotouch弹性成像仪诊断脂肪肝, 使用超声诊断仪检测颈动脉斑块形成。采用ELISA法检测血清HIF-1α、HMGB1和APN水平, 应用二元Logistic回归分析NAFLD合并CAS的影响因素, 应用受试者工作特征曲线下面积(AUC)评估血清指标预测NAFLD患者合并CAS的效能。结果合并CAS组收缩压为(137.1±10.3)mmHg, 显著高于未合并CAS组【(132.9±8.2)mmHg, P<0.05】;合并CAS组血清TC、LDL-C、HIF-1α和HMGB1水平分别为(6.5±2.3)mmol/L、(3.7±0.6)mmol/L、(25.7±6.5)pg/L和(9.4±2.3)ng/ml, 显著高于未合并CAS组【分别(5.1±1.7)mmol/L、(2.8±0.3)mmol/L、(17.2±4.1)pg/L和(6.1±1.5)ng/ml, P<0.05】, 而血清APN为(7.5±3.0)mg/L, 显著低于未合并CAS组【(12.8±4.6)mg/L, P<0.05】;多因素Logistic回归分析显示, TC(OR=1.411, 95%CI: 1.133～1.757)、LDL-C(OR=1.419, 95%CI :1.128～1.785)、HIF-1α(OR=1.504, 95%CI:1.182～1.914)、HMGB1(OR=1.520, 95%CI: 1.206～1.916)和APN(OR=1.530, 95%CI:1.226～1.909)均是影响NAFLD患者合并CAS的独立危险因素(P<0.05);ROC曲线分析显示, 血清HIF-1α、HMGB1和APN水平联合预测NAFLD患者合并CAS的AUC为0.863, 其敏感度为94.5%, 特异度为75.0%, 优于各指标单独预测(P<0.05)。结论 NAFLD患者血清HIF-1α和HMGB1水平升高而血清APN水平降低是发生CAS的危险因素, 应及时发现和给予必要的干预。

关键词: 非酒精性脂肪性肝病, 颈动脉斑块形成, 低氧诱导因子-1α, 高迁移率族蛋白1, 脂联素, 诊断

Abstract: Objective The aim of this study was to investigate the changes of serum hypoxia inducible factor-1α (HIF-1α), high-mobility group box 1 (HMGB1) and adiponectin (APN) levels in patients with non-alcoholic fatty liver diseases (NAFLD) and their correlation to carotid atherosclerosis (CAS). Methods 158 patients with NAFLD, including concomitant CAS in 71 cases, were encountered in our hospital between May 2018 and March 2023, and the NAFLD was diagnosed based on Fibrotouch detection and the CAS was determined by ultrasonography. Serum HIF-1α, HMGB1 and APN levels were assayed by ELISA, the risk factors was revealed by multivariate Logistic regression analysis and predicting performance was evaluated by the area under the receiver operating characteristic curve (AUC). Results The systolic blood pressure in patients NAFLD and concomitant CAS was(137.1±10.3)mmHg, much higher than in NAFLD patients without CAS; serum TC, LDL-C, HIF-1α and HMGB1 levels were (6.5±2.3)mmol/L, (3.7±0.6)mmol/L, (25.7±6.5)pg/L and (9.4±2.3)ng/ml, all significantly higher than , while serum APN level was (7.5±3.0)mg/L, much lower than in those without CAS; the multivariate Logistic regression analysis showed that serum TC(OR=1.411, 95%CI:1.133-1.757), LDL-C(OR=1.419, 95%CI:1.128-1.785), HIF-1α(OR=1.504, 95%CI:1.182-1.914), HMGB1(OR=1.520, 95%CI:1.206-1.916) and APN(OR=1.530, 95%CI:1.226-1.909) were all the risk factors impacting CAS occurrence in patient with NAFLD (P<0.05); the ROC analysis demonstrated that the AUC was 0.863, with the sensitivity of 94.5% and the specificity of 75.0% when the combination of serum HIF-1α, HMGB1 and APN levels was applied to predict the CAS existence, much superior to any single parameter did (P<0.05). Conclusion The elevated serum HIF-1α and HMGB1 levels and the decreased serum APN level are all risk factors for the occurrence of CAS in patients with NAFLD, which might be intervened as sooner as possible.

Key words: Non-alcoholic fatty liver diseases, Carotid atherosclerosis, Hypoxia inducible factor-1α, High-mobility group box 1, Adiponectin, Diagnosis

郑波, 哈丽达·夏尔甫哈孜, 谈理. 非酒精性脂肪性肝病患者血清HIF-1α、HMGB1和脂联素水平变化及其与颈动脉粥样硬化的关系研究^*[J]. 实用肝脏病杂志, 2024, 27(2): 198-201.

Zheng Bo, Halida.Xiaerfuhazi, Tan Li. Changes of serum HIF-1α, HMGB1 and adiponectin levels in patients with non-alcoholic fatty liver diseases and their correlation to carotid atherosclerosis[J]. Journal of Practical Hepatology, 2024, 27(2): 198-201.

参考文献

[1] Flessa CM, Kyrou I, Nasiri-Ansari N, et al. Endoplasmic reticulum stress and autophagy in the pathogenesis of non-alcoholic fatty liver disease (NAFLD): current evidence and perspectives. Curr Obes Rep,2021,10(2):134-161.
[2] Tilg H, Adolph TE, Dudek M, et al. Non-alcoholic fatty liver disease: theinterplay between metabolism, microbes and immunity. Nat Metab,2021,3(12):1596-1607.
[3] Mantovani A, Byrne CD, Benfari G, et al. Risk of heart failure in patients with nonalcoholic fatty liver disease: JACC review topic of the week. J Am Coll Cardiol, 2022,79(2):180-191.
[4] Reiff T, Eckstein HH, Mansmann U, et al. Carotid endarterectomy or stenting or best medical treatment alone for moderate-to-severe asymptomatic carotid artery stenosis: 5-year results of a multicentre, randomised controlled trial. Lancet Neurol,2022,21(10):877-888.
[5] Wang P, Zeng G, Yan Y, et al. Disruption of adipocyte HIF-1α improves atherosclerosis through the inhibition of ceramide generation. Acta Pharm Sin B,2022,12(4):1899-1912.
[6] Kake S, Kawaguchi H, Nagasato T, et al. Association between HMGB1 and thrombogenesis in a hyperlipaemia-induced microminipig model of atherosclerosis. In Vivo,2020,34(4):1871-1874.
[7] Iioka M, Fukuda S, Maeda N, et al. Time-series change of serum soluble T-cadherin concentrations and its association with creatine kinase-MB levels in ST-segment elevation myocardial infarction. J Atheroscler Thromb,2022,29(12):1823-1834.
[8] Kobayashi T, Imachi H, Fukunaga K, et al. HDL promotes adiponectin gene expression via the CAMKK/CAMKIV pathway. J Mol Endocrinol,2022,68(2):89-98.
[9] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪肝专家委员会.非酒精性脂肪性肝病防治指南 (2018年版).实用肝脏病杂志,2018,21(2):177-186.
[10] 中华医学会外科学分会血管外科学组.颈动脉狭窄诊治指南.中国血管外科杂志(电子版),2017,2(3):169-175.
[11] Halliday A, Bulbulia R, Bonati LH, et al. Second asymptomatic carotid surgery trial (ACST-2): a randomised comparison of carotid artery stenting versus carotid endarterectomy. Lancet,2021,398(10305):1065-1073.
[12] Konyn P, Alshuwaykh O, Dennis BB, et al. Gallstone disease and its association with nonalcoholic fatty liver disease, all-cause and cause-specific mortality. Clin Gastroenterol Hepatol,2023,21(4):940-948,e2.
[13] Sato I, Yamamoto S, Kakimoto M, et al. Suppression of nitric oxide synthase aggravates non-alcoholic steatohepatitis and atherosclerosis in SHRSP5/Dmcr rat via acceleration of abnormal lipid metabolism. Pharmacol Rep,2022,74(4):669-683.
[14] Wang CH, Liu HM, Chang ZY, et al. Losartan prevents hepatic steatosis and macrophage polarization by inhibiting HIF-1α in a murine model of NAFLD. Int J Mol Sci,2021,22(15):784-788.
[15] Wang X, de Carvalho Ribeiro M, Iracheta-Vellve A, et al. Macrophage-specific hypoxia-inducible factor-1α contributes to impaired autophagic flux in nonalcoholic steatohepatitis. Hepatology,2019,69(2):545-563.
[16] Skrypnik D, Skrypnik K, Suliburska J, et al. Cardiac rehabilitation may influence leptin and VEGF A crosstalk in patients after acute coronary syndrome. Sci Rep,2022,12(1):825-828.
[17] Xu Z, Xi F, Deng X, et al. Osteopontin promotes macrophage m1 polarization by activation of the JAK1/STAT1/HMGB1 signaling pathway in nonalcoholic fatty liver disease. J Clin Transl Hepatol,2023,11(2):273-283.
[18] Qin Y, Li X, Shi L,et al. The Expression of High Mobility Group Box-1 (HMG1) in the Peripheral Blood and Its Relation with Systemic Vasculitis Patients. Iran J Public Health,2023,52(11):2390-2401.
[19] Lu Z, Liu L, Zhao S, et al. Apigenin attenuates atherosclerosis and non-alcoholic fatty liver disease through inhibition of NLRP3 inflammasome in mice. Sci Rep,2023,13(1):996-999.
[20] Lian K, Feng YN, Li R, et al. Middle- and high-molecular weight adiponectin levels in relation to nonalcoholic fatty liver disease. J Clin Lab Anal,2020,34(4):148-151.

非酒精性脂肪性肝病患者血清HIF-1α、HMGB1和脂联素水平变化及其与颈动脉粥样硬化的关系研究^*

Changes of serum HIF-1α, HMGB1 and adiponectin levels in patients with non-alcoholic fatty liver diseases and their correlation to carotid atherosclerosis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	徐京杭, 于岩岩, 徐小元. 肝硬化临床研究进展[J]. 实用肝脏病杂志, 2024, 27(2): 161-164.
[2]	高洋, 张静, 卢宣霖. 非酒精性脂肪性肝病患者血清IL-1RA、CTRP13和CK-18水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2024, 27(2): 185-188.
[3]	郭萌, 郭琦, 张峰. 超声瞬时弹性成像检测受控衰减参数评估非酒精性脂肪性肝病患者肝脂肪变程度价值研究^*[J]. 实用肝脏病杂志, 2024, 27(2): 189-192.
[4]	李敏, 张丽, 曾艾, 刘世裕. 2型糖尿病合并非酒精性脂肪性肝病患者肝纤维化检出率及预测因素分析^*[J]. 实用肝脏病杂志, 2024, 27(2): 193-197.
[5]	童静, 张珂瓈, 李昌平. 非酒精性脂肪性肝炎患者血清前神经降压素和微小RNA-122水平变化及其诊断脂肪性肝炎的价值探讨^*[J]. 实用肝脏病杂志, 2024, 27(2): 202-205.
[6]	朱春芬, 任春霖, 郭霞. 血清NT-ProBNP和TnI联合心电图检查早期诊断肝硬化性心肌病价值研究^*[J]. 实用肝脏病杂志, 2024, 27(2): 242-245.
[7]	冯彦菲, 苏明华, 殷倩冰, 黎清梅, 苏土梅, 梁蘅恺, 韦璐, 黄建芳, 江建宁. 一组非肝硬化性门静脉高压症病因分析和诊断路径探讨^*[J]. 实用肝脏病杂志, 2024, 27(2): 246-250.
[8]	哈鹏, 苏晓晨, 付宾鹏. 三期增强CT扫描联合血清AFP和VEGF水平诊断肝细胞癌患者临床研究^*[J]. 实用肝脏病杂志, 2024, 27(2): 251-254.
[9]	谢晶美, 刘浩, 李安, 李华, 陈苗苗, 郭宝琴, 石洋洋, 朱志敏, 郭晨光. 动态增强MRI定量参数术前评估原发性肝癌患者临床分期研究^*[J]. 实用肝脏病杂志, 2024, 27(2): 255-258.
[10]	崔甜甜, 张海波, 陈莉莉. 能谱CT增强扫描参数鉴别诊断肝血管瘤与肝细胞癌价值研究^*[J]. 实用肝脏病杂志, 2024, 27(2): 275-278.
[11]	魏野, 汪施妤, 葛高华, 井桂银. CT增强扫描与磁共振检查诊断肝血管瘤和肝细胞癌价值分析^*[J]. 实用肝脏病杂志, 2024, 27(2): 279-282.
[12]	贾永利, 王鹏川, 郭伟, 孙东莹. 低频与高频超声联合诊断胆囊息肉样病变价值分析^*[J]. 实用肝脏病杂志, 2024, 27(2): 307-310.
[13]	章正威, 夏德鑫, 朱宝林, 章应峰, 王翔, 张彤. 早期原发性胆囊癌增强磁共振和CT扫描征象分析^*[J]. 实用肝脏病杂志, 2024, 27(2): 311-313.
[14]	诸葛宇征. 重视内脏静脉血栓形成的诊断和管理^*[J]. 实用肝脏病杂志, 2024, 27(1): 1-2.
[15]	鲁文婷, 张峰. 非肝硬化门静脉系统血栓形成临床管理[J]. 实用肝脏病杂志, 2024, 27(1): 7-10.